Phase I Results for Enasidenib in AML
June 7th 2017Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I dose escalation and expansion study of enasidenib in mutant <em>IDH-2</em> relapsed or refractory acute myeloid leukemia (AML) during the 2017 ASCO Annual Meeting.
Read More
Early Results Show High Response Rate Achieved With BCMA CAR T-cell Therapy in Multiple Myeloma
June 6th 2017Treatment with chimeric antigen receptor (CAR) T cells that target B-cell maturation protein (BMCA) achieved clinical remissions in 33 out of 35 patients (94%) with relapsed or refractory multiple myeloma in early results from a Chinese study presented at the 2017 ASCO Annual Meeting.
Read More
Epacadostat Added to Pembrolizumab is a Promising Combination in Bladder Cancer
June 6th 2017When epacadostat, an IDO1 inhibitor, was combined with pembrolizumab (Keytruda), a PD-1 inhibitor, responses were seen in 35% of patients with advanced urothelial carcinoma, according to findings presented during the 2017 ASCO Annual Meeting.
Read More
Responses Stimulated Across All Tumor Types Harboring TRK Fusions With Larotrectinib
June 6th 2017Larotrectinib (LOXO-101), the novel pan-TRK inhibitor, induced responses in 3 out of 4 patients with a <em>TRK</em> fusion–positive solid tumor, according to findings presented in a press conference June 3 at the 2017 ASCO Annual Meeting.
Read More
Comparing Bosutinib Versus Imatinib in Newly Diagnosed CML
June 6th 2017Jorge Cortes, MD, deputy chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses initial results from the BFORE trial, which is exploring bosutinib (Bosulif) versus imatinib (Gleevec) for newly diagnosed chronic myeloid leukemia.
Read More
Ipatasertib/Paclitaxel as First-Line Therapy Improved PFS in Triple-Negative Breast Cancer
June 6th 2017The experimental AKT inhibitor ipatasertib in combination with paclitaxel improved progression-free survival (PFS) as a first-line therapy for patients with locally advanced or metastatic triple-negative breast cancer when compared with paclitaxel alone, according to initial findings of the LOTUS trial presented during the 2017 ASCO Annual Meeting.<br />
Read More
Alectinib Improved PFS by 15 Months Over Crizotinib in ALK+ NSCLC in ALEX Trial
June 5th 2017Second-generation ALK inhibitor alectinib (Alecensa) demonstrated a 15-month improvement in progression-free survival compared with crizotinib (Xalkori), the first-generation ALK inhibitor and standard of care, in patients with <em>ALK</em>-positive non–small cell lung cancer.
Read More
Lurbinectedin Active in Endometrial Cancer as Monotherapy and in Combination Regimens
June 5th 2017Lurbinectedin (PM01183) shows activity as a single agent as well as in combination with doxorubicin or paclitaxel in patients with advanced endometrial cancer, according to findings presented during the 2017 ASCO Annual Meeting.
Read More
In updated findings from the KEYNOTE-059 trial of pembrolizumab in advanced gastric or gastroesophageal junction (GEJ) cancer, the PD-1 inhibitor maintained signs of its clinical benefit in this patient population, which is encouraging as the indication is currently under consideration for approval with the FDA.
Read More
Results of the LATITUDE Trial in High-Risk Metastatic Hormone-Naive Prostate Cancer
June 5th 2017Kim Chi, MD, professor, University of British Columbia, discusses results of the phase III LATITUDE trial of androgen deprivation therapy with abiraterone acetate plus prednisone (Deltasone) or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
Read More
Niraparib Improves Responses in Recurrent Ovarian Cancer, Analysis Shows
June 5th 2017The PARP inhibitor niraparib (Zejula) provided significant benefits in patients with recurrent ovarian cancer who had a partial response, with similar treatment effects in patients with or without germline <em>BRCA</em> mutations, according to a post-hoc analysis of data from the ENGOT-OV16/NOVA trial presented at the 2017 ASCO Annual Meeting.
Read More
Reducing oxaliplatin-based chemotherapy by half could benefit patients with low-risk advanced colon cancer receiving chemotherapy after surgery. The 50% decrease would not notably increase their recurrence risk and would decrease the chances of developing neuropathy, according to findings presented at the 2017 ASCO Annual Meeting.
Read More
ProfiLER Study Demonstrates Importance of Genomic Testing for Precision Medicine
June 4th 2017Comprehensive genomic testing is not yet widespread, but a French study presented at the 2017 ASCO Annual Meeting suggested that DNA profiling can be of important value in advancing personalized medicine. Patients who received molecularly targeted agents based on genomic profiles had longer 3-year and 5-year overall survival than those who did not.
Read More
A new, high-intensity genomic sequencing approach for circulating tumor DNA uncovered at least 1 genetic change in both the tumor DNA and the blood of 89% of patients, demonstrating a high rate of concordance between 2 approaches for detecting molecular aberrations, according to a study presented at the 2017 ASCO Annual Meeting.
Read More
Abemaciclib Added to Fulvestrant Improves Response in HR+/HER2- Breast Cancer
June 4th 2017The risk of disease progression or death was reduced by 45% with the addition of abemaciclib to fulvestrant compared with that of fulvestrant alone in patients with previously treated HR-positive/HER2-negative breast cancer, according to findings presented during the 2017 ASCO Annual Meeting.
Read More
Earlier intervention with abiraterone acetate (Zytiga) lowered the risk of death by nearly 40% for men with high-risk advanced or metastatic prostate cancer who were newly diagnosed or had not yet received hormone therapy in findings from 2 clinical trials presented at the 2017 ASCO Annual Meeting.
Read More
Efficacy Results for LOXO-101 in TRK Fusion Cancers
June 3rd 2017David Hyman, MD, Chief of Early Drug Development, Memorial Sloan Kettering Cancer Center, discusses efficacy results for larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.
Read More
Updated Results of MONALEESA-2 Trial Maintain Benefit of Ribociclib in HR+/HER2- Breast Cancer
June 3rd 2017Updated results from the phase III MONALEESA-2 trial presented during the 2017 ASCO Annual Meeting confirmed the benefit of frontline ribociclib (Kisqali) in combination with letrozole in patients with postmenopausal hormone receptor (HR)-positive, HER2-negative advanced breast cancer. The combination showed a progression-free survival (PFS) benefit of 9.3 months compared with letrozole plus placebo.
Read More
Survivors of Testicular Cancer At Risk Due to Low Testosterone Levels
June 3rd 2017Chronic health issues, including high blood pressure, diabetes, erectile dysfunction, anxiety, or depression were noted in nearly 40% of testicular cancer survivors with low testosterone levels compared with survivors who had normal levels of testosterone, according to findings from a study that were released at the 2017 ASCO Annual Meeting.
Read More
Efficacy and Biomarker Results for Pembrolizumab in Soft Tissue and Bone Sarcomas
June 3rd 2017Lisa H. Butterfield, PhD, discusses efficacy and biomarker results of the phase II SARC028 study, which explored pembrolizumab (Keytruda) in advanced soft tissue and bone sarcomas, during the 2017 ASCO Annual Meeting.
Read More
Healthy Lifestyle Linked to Improved Overall Survival, Reduced Recurrence in Colon Cancer
May 19th 2017Results from a recent study showed patients with stage III colorectal cancer experienced a 42% lower chance of death and a trend toward reduced cancer recurrence if they maintained a healthy body weight, engaged in regular physical activity, and adopted other healthy lifestyle behaviors.
Read More
Poor Uptake Limits Otherwise Impressive Potential of HPV Vaccine
May 18th 2017Efficacy results for the human papillomavirus (HPV) vaccine continue to be impressive, with newly reported findings showing it reduced the prevalence of high-risk oral HPV infections by 88% in young adults who had at least 1 dose of the vaccine.
Read More
Affordable Care Act Associated With Shift to Earlier-Stage Cancer Diagnosis
May 18th 2017More Stage I cancers were diagnosed after the passage of the Affordable Care Act within 5 screenable disease types (colorectal cancer, female breast cancer, cervical cancer, lung cancer, and prostate cancer) than were diagnosed before ACA implementation.
Read More
FGFR Pathway Genetic Aberrations May Be Key to Targeting Cholangiocarcinoma
June 11th 2016The advent of targeted inhibitors that work on the fibroblast growth factor receptor (FGFR) pathway may alter the disease course and outcomes in intrahepatic cholangiocarcinoma, suggests data from a four-center retrospective study. Lead investigator Apurva Jain, MD, of the University of Texas MD Anderson Cancer Center presented the findings at the 2016 ASCO Annual Meeting.
Read More
Largest-Ever Liquid Biopsy Study Increases Favor for Mutation Testing Method
June 9th 2016The liquid biopsy testing method from a large genomic analysis of circulating tumor DNA (ctDNA) in blood samples from more than 15,000 patients, was found to be closely correlated with mutations described in databases, and often from tumor biopsies as well, according to research presented at the 2016 ASCO Annual Meeting.
Read More
Heparan Sulfate-Like Drug Active in Pancreatic Cancer
June 9th 2016Half of patients with metastatic pancreatic cancer had objective responses when treated with a novel inhibitor of heparin-binding growth factors in addition to conventional chemotherapy, a small preliminary clinical trial showed.
Read More